Mounjaro vs Ozempic

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both once-weekly injections FDA-approved for type 2 diabetes -- but they are not the same drug. Mounjaro acts on two incretin receptors (GIP and GLP-1); Ozempic acts on one (GLP-1). That mechanistic difference is the main reason Mounjaro consistently produced greater weight loss and larger A1C reductions in clinical trials. The head-to-head SURMOUNT-5 trial (Eli Lilly, May 2025) confirmed tirzepatide's weight-loss advantage at maximum tolerated doses. Across pivotal single-arm trials, tirzepatide 15 mg reached roughly 22.5% mean weight loss (SURMOUNT-1, 72 weeks) versus about 14.9% for semaglutide 2.4 mg (STEP 5, 104 weeks) -- cross-trial, so the comparison is directional rather than definitive. Ozempic's one meaningful edge: a separate FDA approval to reduce heart attack and stroke risk in adults with type 2 diabetes and established cardiovascular disease. Mounjaro does not yet carry that indication.

Key Takeaways

• Mechanism: Mounjaro targets two incretin receptors (GIP and GLP-1); Ozempic targets one (GLP-1). The dual mechanism is the primary reason Mounjaro produced greater weight loss in clinical trials.
• FDA-approved uses: Both are approved for type 2 diabetes. Ozempic has an additional cardiovascular-risk-reduction indication (2020). Neither is FDA-approved for weight loss on its own label — that's Wegovy (same ingredient as Ozempic) and Zepbound (same ingredient as Mounjaro).
• Head-to-head data: SURMOUNT-5 (results May 2025) is the direct comparison. Tirzepatide produced statistically superior weight loss. This is the most reliable efficacy comparison.
• Weight loss in separate trials: Mounjaro 15 mg → ~22.5% (SURMOUNT-1, 72 weeks, non-diabetic obesity). Ozempic 2.4 mg → ~14.9% (STEP 5, 104 weeks, non-diabetic obesity).
• A1C reduction in type 2 diabetes: Mounjaro → roughly 2.0-2.4% (SURPASS trials). Ozempic → roughly 1.5-1.8% (SUSTAIN trials).
• Dosing: Both are once-weekly subcutaneous injections. Mounjaro titrates 2.5 → 15 mg. Ozempic titrates 0.25 → 2 mg.
• Common side effects: Nausea, diarrhea, vomiting, constipation — most common with both. Frequency is broadly similar.
• Cost: List prices are $1,000-$1,400 per month without insurance. Actual cost depends on plan, savings cards, and whether the drug is covered for your specific indication.

Mechanism: Dual Agonist vs Single Agonist

Mounjaro and Ozempic work through overlapping but meaningfully different mechanisms. Ozempic mimics glucagon-like peptide-1 (GLP-1), a gut hormone released after meals that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central brain receptors. Mounjaro does all of that and simultaneously activates the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is the body's other major incretin hormone, and in the context of a GLP-1 agonist it appears to amplify the overall metabolic response. The dual activation is widely cited as the mechanistic explanation for the greater weight loss observed with tirzepatide.

Clinical Trial Data

Both drugs were evaluated in large, randomized, placebo-controlled programs. The results below come from separate trial programs. Cross-trial comparisons have well-known limitations (different patient populations, different durations, different definitions of endpoint) and should be interpreted with caution.

• SURMOUNT-1 (Mounjaro): Published in New England Journal of Medicine (Jastreboff et al., 2022). 2,539 adults with BMI ≥30 or ≥27 plus comorbidity, without type 2 diabetes. At 72 weeks, tirzepatide 15 mg weekly produced mean weight loss of about 22.5% versus 2.4% with placebo.
• STEP 5 (Ozempic dose used in Wegovy): Published in Nature Medicine (Garvey et al., 2022). 304 adults with BMI ≥30 or ≥27 plus comorbidity, without type 2 diabetes. At 104 weeks, semaglutide 2.4 mg weekly produced mean weight loss of about 14.9% versus 2.1% with placebo.
• SURMOUNT-5 (head-to-head): Topline results reported by Eli Lilly in May 2025. Adults with obesity without diabetes, maximum tolerated doses of each drug. Tirzepatide produced statistically superior weight loss versus semaglutide. This is the most rigorous direct comparison to date.

FDA-Approved Uses

Use	Mounjaro	Ozempic
Type 2 diabetes (adjunct to diet and exercise)	✅ Yes (2022)	✅ Yes (2017)
Cardiovascular risk reduction (adults with T2D and established CVD)	❌ No	✅ Yes (2020)
Chronic weight management	❌ No (use Zepbound — same ingredient)	❌ No (use Wegovy — same ingredient)

Both drugs are frequently prescribed off-label for weight loss in patients without diabetes, but "off-label" is a real distinction that affects insurance coverage, prescribing clinician comfort, and legal status. If weight loss is the primary goal, Zepbound (tirzepatide) and Wegovy (semaglutide) are the on-label choices.

Which Is Right for You?

Neither drug is universally best. A practical framework:

1. If your primary goal is type 2 diabetes management, both are on-label. Ozempic has the added cardiovascular-risk-reduction indication, which matters if you have established CVD. Mounjaro generally produces greater A1C reduction in SURPASS trials.
2. If your primary goal is weight loss, look at Zepbound or Wegovy instead — they're the same active ingredients as Mounjaro and Ozempic but approved specifically for chronic weight management.
3. Consider insurance coverage. A drug that your plan covers is usually a better practical choice than a marginally more effective drug it does not. Coverage for weight-loss indications remains inconsistent.
4. Talk to your clinician. Contraindications (personal or family history of medullary thyroid carcinoma, MEN 2, prior pancreatitis) matter, and individual tolerability varies meaningfully between patients.